Dropprint GenomicsWinter 2020Acquired☆Watch⊞Compare

Dropprint Genomics is one of 233 Biotech companies tracked from San Francisco, CA, USA, on record since 2020. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

The better way to run single cell genomics

Who we are? We write software that understands the activity of individual cells as opposed to all cells. This approach is novel because we are no longer looking at average signals and can be precise. It is like a police person trying to identify the speeding car, they won’t find it if they look at all the cars at once, rather they need to look at the speed of each individual car. This is the beauty of single cell genomics, we can now identify that speeding car. Why now? The biggest barrier for entry into the single cell genomics market are cost and data analysis. To that end, we have reduced the cost by 10-fold and built the computational infrastructure for scalability. Although single cell sequencing has only been around for about five years, we come from one of the top single cell genomics labs and were the first to process and analyze millions of immune cells. Thanks to our software solutions, we have been able to bring big data solutions to the immune system. Where are we and where are we going? We have generated a database of over 1 million immune cells spanning healthy, cancerous, and autoimmune immune cells and are growing through paid partnerships. Harnessing out database and ML software, we can take a data-centric approach for better target discovery. Fortunately, as our database continues to grow, our models will continue to learn for more precise, unbiased, and automated single cell genomics. Thank you!

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Dropprint Genomics is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Dropprint Genomics sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Dropprint Genomics, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.